{"id":"azd2936","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nasopharyngitis"},{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Pyrexia"},{"rate":"5-10%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL5314706","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, AZD2936 reduces the activity of the PI3K/AKT signaling pathway, which is involved in the regulation of immune cell function. This leads to a decrease in the proliferation and survival of immune cells, resulting in anti-inflammatory effects.","oneSentence":"AZD2936 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:17.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":878},{"nctId":"NCT04995523","phase":"PHASE1, PHASE2","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-14","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":212},{"nctId":"NCT05123482","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer","enrollment":460},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT07161414","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-25","conditions":"Advanced Solid Tumors","enrollment":40},{"nctId":"NCT07221253","phase":"PHASE3","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-04","conditions":"Biliary Tract Cancer","enrollment":1100},{"nctId":"NCT06357533","phase":"PHASE3","title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-11","conditions":"Non-Small Cell Lung Cancer","enrollment":675},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT06764875","phase":"PHASE3","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-01","conditions":"HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":840},{"nctId":"NCT06868277","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-10","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":830},{"nctId":"NCT05414032","phase":"PHASE2","title":"Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-07-12","conditions":"Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)","enrollment":102},{"nctId":"NCT06692738","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-18","conditions":"Non-small Cell Lung Cancer","enrollment":880},{"nctId":"NCT06996782","phase":"PHASE1, PHASE2","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":152},{"nctId":"NCT07431281","phase":"PHASE3","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-03","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer","enrollment":2130},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT05775159","phase":"PHASE2","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-24","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":294},{"nctId":"NCT03819465","phase":"PHASE1","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-27","conditions":"Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":175},{"nctId":"NCT07098338","phase":"PHASE2","title":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-07","conditions":"Non-Small Cell Lung Cancer","enrollment":278},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT04612751","phase":"PHASE1","title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-02","conditions":"Advanced or Metastatic NSCLC","enrollment":155},{"nctId":"NCT06630130","phase":"PHASE2","title":"Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer","status":"RECRUITING","sponsor":"Jeeyun Lee","startDate":"2025-01-22","conditions":"Stomach Neoplasms","enrollment":50},{"nctId":"NCT04686305","phase":"PHASE1","title":"Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-03-09","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":244},{"nctId":"NCT06366451","phase":"EARLY_PHASE1","title":"PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC","status":"RECRUITING","sponsor":"Presage Biosciences","startDate":"2024-05-22","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT04541108","phase":"EARLY_PHASE1","title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","status":"RECRUITING","sponsor":"Presage Biosciences","startDate":"2021-07-26","conditions":"Solid Tumor","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rilvegostomig","Rilvegostomig"],"phase":"phase_2","status":"active","brandName":"AZD2936","genericName":"AZD2936","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD2936 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsing multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}